Michele Cavo

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. doi Role of consolidation therapy in transplant eligible multiple myeloma patients
    Michele Cavo
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Electronic address
    Semin Oncol 40:610-7. 2013
  2. doi Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Blood 120:9-19. 2012
  3. doi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010
  4. ncbi Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
    Michele Cavo
    Dipartimento di Ematologia e Scienze Oncologiche Seràgnoli, Istituto di Ematologia Seragnoli, Universita di Bologna, Bologna, Italy
    J Clin Oncol 27:5001-7. 2009
  5. doi Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
    Lucia Pantani
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Ann Hematol 93:123-8. 2014
  6. ncbi Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
    Michele Cavo
    Istituto di Ematologia ed Oncologia Medica Seràgnoli, Universita di Bologna, Bologn, Italy
    J Clin Oncol 25:2434-41. 2007
  7. ncbi Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138, Bologna, Italy
    Blood 106:35-9. 2005
  8. doi Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Blood 118:5989-95. 2011
  9. doi Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Ann Hematol 91:419-26. 2012
  10. doi Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency
    Patrizia Tosi
    Institute of Hematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Biol Blood Marrow Transplant 16:1115-21. 2010

Detail Information

Publications40

  1. doi Role of consolidation therapy in transplant eligible multiple myeloma patients
    Michele Cavo
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Electronic address
    Semin Oncol 40:610-7. 2013
    ..This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients. ..
  2. doi Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Blood 120:9-19. 2012
    ..VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484...
  3. doi Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
    Michele Cavo
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Lancet 376:2075-85. 2010
    ....
  4. ncbi Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma
    Michele Cavo
    Dipartimento di Ematologia e Scienze Oncologiche Seràgnoli, Istituto di Ematologia Seragnoli, Universita di Bologna, Bologna, Italy
    J Clin Oncol 27:5001-7. 2009
    ..To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM)...
  5. doi Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
    Lucia Pantani
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Ann Hematol 93:123-8. 2014
    ..Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy. Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse...
  6. ncbi Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
    Michele Cavo
    Istituto di Ematologia ed Oncologia Medica Seràgnoli, Universita di Bologna, Bologn, Italy
    J Clin Oncol 25:2434-41. 2007
    ..We performed a prospective, randomized study of single (arm A) versus double (arm B) autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM)...
  7. ncbi Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138, Bologna, Italy
    Blood 106:35-9. 2005
    ..Thal-Dex may be considered an effective and relatively well-tolerated oral alternative to the more complex VAD regimen as front-line therapy for MM patients who are candidates for subsequent autologous transplantation...
  8. doi Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Blood 118:5989-95. 2011
    ..PET/CT involvement at diagnosis, after novel agent-based induction and subsequent ASCT is a reliable predictor of prognosis in MM patients. This study is registered at www.clinicaltrials.gov as NTC01341262...
  9. doi Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma
    Elena Zamagni
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Ann Hematol 91:419-26. 2012
    ..TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8%)...
  10. doi Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency
    Patrizia Tosi
    Institute of Hematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Biol Blood Marrow Transplant 16:1115-21. 2010
    ..Given the relationship between recovery of renal function and response to induction treatment, more intensive Thal + bortezomib regimens could be explored to rescue higher numbers of patients...
  11. doi Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials
    Pieter Sonneveld
    Pieter Sonneveld, Erasmus Medical Center, Rotterdam Henk M Lokhorst, Utrecht Medical Center, Utrecht, the Netherlands Hartmut Goldschmidt, University Hospital of Heidelberg, Heidelberg, Germany Laura Rosiñol, Joan Bladé, Hospital Clinic de Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain Michele Cavo, Paola Tacchetti, Elena Zamagni, Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy Michel Attal, Hopital Purpan, Toulouse Philippe Moreau, University Hospital, Nantes, France Avinash Desai, Janssen Global Services Kevin Liu, Janssen Research and Development, Raritan, NJ Dixie Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA Andrew Cakana, Janssen Research and Development, High Wycombe, United Kingdom Helgi van de Velde, Baylor College of Medicine/The Methodist Hospital
    J Clin Oncol 31:3279-87. 2013
    ..To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma...
  12. pmc 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma
    Cristina Nanni
    Nuclear Medicine, PET Unit, Policlinico S Orsola Malpighi, Bologna University, Italy
    World J Surg Oncol 5:68. 2007
    ..Whole body skeletal survey (WBSS), Magnetic resonance (MR) and 18F-FDG PET/CT are imaging techniques routinely used for the evaluation of bone involvement in MM patients...
  13. ncbi Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma
    Patrizia Tosi
    Institute of Hematology and Medical Oncology, Seragnoli University of Bologna, Bologna, Italy
    Eur J Haematol 74:212-6. 2005
    ..This latter therapeutic approach has risen the concern of side-effects of long-term therapy with this drug...
  14. ncbi A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma
    Elena Zamagni
    Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 92:50-5. 2007
    ....
  15. ncbi First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
    Patrizia Tosi
    Institute of Hematology and Medical Oncology L e A Seràgnoli Bologna University, Bologna, Italy
    Eur J Haematol 76:399-404. 2006
    ..The evaluation of biochemical markers of bone turnover could allow a dynamic evaluation of the effects of a given therapy on bone metabolism...
  16. doi The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients
    Cristina Nanni
    Department of Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Clin Nucl Med 38:e74-9. 2013
    ..The objective of this study was to analyze the prognostic value of (18)F-FDG PET/CT after therapy in patients with multiple myeloma (MM)...
  17. doi Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
    Elena Zamagni
    Istituto di Ematologia Seragnoli, Universita degli Studi di Bologna, Bologna, Italy
    Semin Thromb Hemost 37:209-19. 2011
    ..As yet, no study has clearly demonstrated a significant superiority of one prophylactic regimen in comparison with the others. Further investigation and more randomized clinical trials are needed to define the best thromboprophylaxis...
  18. ncbi First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138, Bologna, Italy
    Haematologica 89:826-31. 2004
    ....
  19. ncbi Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation
    Patrizia Tosi
    Seràgnoli Institute of Hematology and Medical Oncology, Bologna University, Bologna, Italy
    Eur J Haematol 80:31-6. 2008
    ..5640 pmol/L +/- 859 SE P = 0.02) Our results indicate that, at variance to what has been previously reported, bone resorption is more prominent in t(4;14) positive patients...
  20. ncbi 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone
    Cristina Nanni
    Department of Nuclear Medicine, Policlinico S Orsola Malpighi, Bologna, Italy
    In Vivo 22:513-7. 2008
    ..To evaluate the value of 18F-fluorodeoxy-glucose (FDG) positron emission tomography with computed tomography (PET/CT) in myeloma in patients presenting with a solitary plasmacytoma of bone (SPB)...
  21. doi Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation
    Carolina Terragna
    Istituto di Ematologia Seragnoli, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale DIMES, Universita degli Studi di Bologna, Via Massarenti, 9 40138, Bologna, Italy
    Ann Hematol 92:1271-80. 2013
    ..These results can be an important first step to identify at diagnosis those patients who will respond more favourably to a particular treatment strategy...
  22. doi Current status of bortezomib in the treatment of multiple myeloma
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Curr Hematol Malig Rep 2:128-37. 2007
    ..Bortezomib may be the "backbone" for the development of more effective treatment strategies to improve patient outcome in multiple myeloma...
  23. ncbi The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
    Annamaria Brioli
    Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK Istituto di Ematologia Seràgnoli, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Br J Haematol 165:441-54. 2014
    ..In this review current knowledge of intra-clonal heterogeneity, as well as its impact on the different components of MM treatment is discussed. ..
  24. ncbi Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
    Patrizia Tosi
    Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Eur J Haematol 73:98-103. 2004
    ..In conclusion, our data show that thalidomide can be safely administered in patients with advanced MM and renal failure...
  25. doi Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
    Antonio Palumbo
    University of Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Torino, Italy
    J Clin Oncol 29:986-93. 2011
    ....
  26. doi First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies
    Gabriele Gugliotta
    Institute of Hematology L e A Seràgnoli, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy
    Drugs 74:627-43. 2014
    ..We reviewed the impact of age on the first-line treatment of CP CML patients in the TKI era, considering the epidemiology of the disease, the role of comorbidities, and analyzing data from population-based studies and clinical trials. ..
  27. pmc International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
    Michele Cavo
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Blood 117:6063-73. 2011
    ..This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients...
  28. ncbi Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
    Antonio Curti
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 139:415-24. 2007
    ..In conclusion, sc injections of cryopreserved Id-pulsed DCs were safe and, in contrast with intravenous administrations, induced anti-MM T-cell responses...
  29. ncbi Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results
    Cristina Nanni
    UO Medicina Nucleare, Policlinico S Orsola Malpighi, Via Massarenti, 40100, Bologna, Italy
    Eur J Nucl Med Mol Imaging 33:525-31. 2006
    ..The aim of this study was to compare whole-body X-ray (WBXR), MRI and (18)F-FDG PET/CT in patients with MM...
  30. ncbi Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma
    Patrizia Tosi
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:408-14. 2002
    ..The aim of this study was to evaluate the activity of thalidomide in a large series of MM patients...
  31. ncbi Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study
    Michele Cavo
    Institute of Hematology and Medical Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:934-42. 2002
    ....
  32. doi Gender-related risk of myocardial involvement in systemic amyloidosis
    Claudio Rapezzi
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Amyloid 15:40-8. 2008
    ..In conclusion, these findings raise the hypothesis that some biological characteristic associated with female gender protects against myocardial involvement in familial ATTR...
  33. ncbi Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
    Annamaria Brioli
    Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
    Expert Rev Anticancer Ther 14:581-94. 2014
    ..The issue of continuous treatment in the light of new biological discoveries, including intra-clonal heterogeneity, will also be addressed. ..
  34. pmc International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
    Antonio Palumbo
    Antonio Palumbo and Alessandra Larocca, University of Torino, Torino Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy S Vincent Rajkumar, Mayo Clinic, Rochester, MN Jesus F San Miguel, University Hospital of Salamanca, Salamanca, Spain Ruben Niesvizky, Weill Cornell Medical College, New York, NY Gareth Morgan, Royal Marsden Hospital, London, United Kingdom Ola Landgren, National Cancer Institute, Bethesda, MD Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic Hermann Einsele, University of Wurzburg, Wurzburg, Germany Kenneth C Anderson and Paul G Richardson, Dana Farber Cancer Institute, Boston, MA Meletios A Dimopoulos, University of Athens School of Medicine, Athens, Greece Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia A Keith Stewart, Mayo Clinic, Scottsdale, AZ Kazuyuki Shimizu, Aichi Gakuin Hospital, Department of Physiology
    J Clin Oncol 32:587-600. 2014
    ..To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation...
  35. ncbi Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
    Gabriele Gugliotta
    Department of Experimental, Diagnostic and Specialty Medicine, S Orsola Malpighi Hospital, University of Bologna, Institute of Hematology L e A Seràgnoli, Bologna, Italy
    Expert Rev Hematol 6:563-74. 2013
    ..We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment. ..
  36. doi The role of imaging techniques in the management of multiple myeloma
    Elena Zamagni
    Seràgnoli Institute of Haematology, Bologna University School of Medicine, Bologna, Italy
    Br J Haematol 159:499-513. 2012
    ..Both MRI and PET/CT are predictors of clinical outcome. A prospective use of these newer imaging techniques in both clinical trials and clinical practice may help optimize MM management in the near future...
  37. pmc Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
    Enrica Borsi
    Department of Experimental Diagnostic and Specialty Medicine DIMES, L and A Seragnoli, Bologna University School of Medicine, S Orsola s University Hospital, Italy
    Oncotarget 5:1779-92. 2014
    ..These results show that HIF-1α is an important player in MM homeostasis and that its inhibition by small antisense oligonucleotides provides a rationale for novel therapeutic strategy to improving MM treatment. ..
  38. ncbi Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
    Annamaria Brioli
    Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom Istituto di Ematologia Seràgnoli, Universita degli Studi di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Blood 123:3414-9. 2014
    ..This study was registered at www.isrctn.org as ISRCTN68454111. ..
  39. pmc A risk prediction score for invasive mold disease in patients with hematological malignancies
    Marta Stanzani
    Institute of Hematology, Department of Hematology and Clinical Oncology, Lorenzo e Ariosto Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    PLoS ONE 8:e75531. 2013
    ..A risk score for invasive mold disease (IMD) in patients with hematological malignancies could facilitate patient screening and improve the targeted use of antifungal prophylaxis...
  40. doi Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types
    Claudio Rapezzi
    Istituto di Cardiologia, Policlinico S Orsola Malpighi, Via Massarenti n 9, 40125 Bologna, Italy
    Circulation 120:1203-12. 2009
    ..In this study, we compared the diagnostic/clinical profiles of these 3 types of systemic cardiac amyloidosis...